Trials / Completed
CompletedNCT03663946
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
Drug Use Investigation on Combination Therapy With Yervoy and Opdivo (Unresectable or Metastatic Renal Cell Carcinoma)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 81 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Patients with non-surgical or renal cell carcinoma that has spread who are starting treatment for the first time with Yervoy and Opdivo in the real world
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-Interventional | Non-Interventional |
Timeline
- Start date
- 2018-09-18
- Primary completion
- 2020-05-30
- Completion
- 2020-05-30
- First posted
- 2018-09-10
- Last updated
- 2022-02-25
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03663946. Inclusion in this directory is not an endorsement.